Inspire Medical Systems, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing reveals a company at a crossroads, balancing strong product-level economics against systemic reimbursement and legal headwinds. The transition to the Inspire V system is clearly improving gross margins, but the inability to translate these gains into significant revenue growth suggests that the market is currently constrained by administrative and regulatory friction rather than a lack of demand. Investors must weigh the positive shift in operating cash flow against the reality of a stagnant top line and rising overhead. The reported net loss, while largely an accounting artifact of stock-based compensation tax shortfalls, highlights the volatility of the company's bottom line. The balance sheet remains a primary strength, providing a necessary buffer against the potential costs of ongoing litigation and the DOJ investigation. Ultimately, the trajectory of the stock will likely depend on two catalysts: the resolution of the CPT coding uncertainty and the actual conversion rate of GLP-1 patients into Inspire candidates. If management can secure a dedicated code and prove the GLP-1 funnel theory, the current margin improvements could lead to a powerful earnings breakout. Conversely, continued revenue stagnation and legal losses could validate the bear case of a company struggling to scale its newest technology.